

Tamer Coskun

Discloser Identifier: 1043242

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Employment	Self
Title: Associate VP-Medical Position Description: Clinical research physician for early phase development (Phase 1 and Phase 2) Additional Information:		
Eli Lilly and Company	Stock Option	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1122987

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Employment	Self
Title: Director of Statistics Additional Information:		Position Description: provides statistical leadership to support chronic weight management compound development

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Juan Frias

Discloser Identifier: 1016392

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
89BIO	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> Grants to institution for clinical research <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
89BIO	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Akero	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> Phase 2 clinical trial <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Akero	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Advisor/consultant <i>Additional Information:</i>		
Altimune	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Altimune	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> General consulting on clinical development plans <i>Additional Information:</i>		
Altimune	Other	Self
<i>Category:</i> Other <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
Boehringer Ingelheim	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Entity	Type	Interest Held By
Boehringer Ingelheim	Other	Self
Category: Other Description: Advisory board member Additional Information:		
Boehringer Ingelheim	Consultant	Self
Category: Consultant Description: Consultant for clinical trial program Additional Information:		
Carmot Therapeutics	Grant / Contract	Self
Recipient Name: Velocity Clinical Research Grant / Contract Description: Additional Information: Recipient Type: Institution Grant / Contract Purpose: Research		
Carmot Therapeutics	Consultant	Self
Category: Consultant Description: Additional Information:		
Eli Lilly	Grant / Contract	Self
Recipient Name: Velocity Clinical Research Grant / Contract Description: Additional Information: Recipient Type: Institution Grant / Contract Purpose: Research		
Eli Lilly	Grant / Contract	Self
Recipient Name: Velocity Clinical Research Grant / Contract Description: Additional Information: Recipient Type: Institution Grant / Contract Purpose: Research		
Eli Lilly and Company	Other	Self
Category: Other Description: Scientific advisory boards Additional Information:		
Eli Lilly and Company	Other	Self
Category: Other Description: Speaking engagements Additional Information:		
INTERCEPT PHARMACEUTICALS, INC.	Grant / Contract	Self
Recipient Name: Velocity Clinical Research Grant / Contract Description: Additional Information: Recipient Type: Institution Grant / Contract Purpose: Research		
Janssen Pharmaceuticals, Inc	Grant / Contract	Self
Recipient Name: velocity Clinical Research Grant / Contract Description: Additional Information: Recipient Type: Institution Grant / Contract Purpose: Research		
Madrigal	Grant / Contract	Self

Entity	Type	Interest Held By
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
Merck	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
Merck	Other	Self
<i>Category:</i> Other <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
Merck	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaking engagements <i>Additional Information:</i>		
Northsea Therapeutics	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
Novartis	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
Novo Nordisk	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
Novo Nordisk	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaking engagements <i>Additional Information:</i>		
Novo Nordisk Inc	Other	Self
<i>Category:</i> Other <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
oramed	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
Pfizer	Grant / Contract	Self

Entity	Type	Interest Held By
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Pfizer	Other	Self
<i>Category:</i> Other <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
Sanofi	Grant / Contract	Self
<i>Recipient Name:</i> Velocity Clinical Research <i>Grant / Contract Description:</i> <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
SANOI US SERVICES INC.	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaking engagements <i>Additional Information:</i>		
SANOI US SERVICES INC.	Other	Self
<i>Category:</i> Other <i>Description:</i> Scientific advisory boards <i>Additional Information:</i>		

Additional Questions

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

- What is the manuscript title?

Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

- Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1122989

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Employment	Self
Title: Executive Medical director Additional Information: Position Description: Physician responsible for Global Patient Safety in the Therapeutic area of Endocrinology and Diabetes		
Eli Lilly and Company	Stock	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Mark Hartman

Discloser Identifier: 646466

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Employment	Self
Title: Vice President - Medical - NASH/Obesity (Clinical Research - Diabetes and Complications) Additional Information: Position Description: Development, conduct and reporting of phase 1 and phase 2 global clinical trials in support of clinical development of compounds for the treatment of NAFLD/NASH, obesity and diabetes mellitus.		
Eli Lilly and Company	Stock	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Triple Hormone Receptor Agonist Retatrutide: Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1043243

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Employment	Self
Title: SVP Additional Information: Position Description: Head of Early Clinical Investigations for Diabetes, Obesity and Complications		
Eli Lilly and Company	Stock	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 632173

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Amgen	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
Biohaven Pharmaceuticals, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
Boehringer Ingelheim	Grant / Contract	Self
<i>Recipient Name:</i> Yale University <i>Grant / Contract Description:</i> multi-center trial <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution		<i>Grant / Contract Purpose:</i> Research
Boehringer Ingelheim	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
Eli Lilly and Company	Grant / Contract	Self
<i>Recipient Name:</i> Yale University School of Medicine <i>Grant / Contract Description:</i> Multi-center clinical trial <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution		<i>Grant / Contract Purpose:</i> Research
Eli Lilly and Company	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
Intellihealth	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		

Entity	Type	Interest Held By
Intellihealth	Stock Option	Self
Additional Information: Scientific Advisory Board		
Novo Nordisk	Grant / Contract	Self
Recipient Name: Yale University School of Medicine Grant / Contract Description: Multi-center clinical trial Additional Information: Recipient Type: Institution Grant / Contract Purpose: Research		
Novo Nordisk	Consultant	Self
Category: Consultant Description: Scientific Advisory Board Additional Information:		
Novo Nordisk AS	Consultant	Self
Category: Consultant Description: Scientific Advisory Board Additional Information:		
Pfizer	Consultant	Self
Category: Consultant Description: Scientific Advisory Board Additional Information:		
Rhythm Pharmaceuticals	Grant / Contract	Self
Recipient Name: Yale University School of Medicine Grant / Contract Description: Multi-center clinical trial Additional Information: Recipient Type: Institution Grant / Contract Purpose: Research		
Rhythm Pharmaceuticals	Consultant	Self
Category: Consultant Description: Scientific Advisory Board Additional Information:		
Scholar Rock	Consultant	Self
Category: Consultant Description: Scientific Advisory Board Additional Information:		
Structure Therapeutics	Consultant	Self
Category: Consultant Description: Scientific Advisory Board Additional Information:		
Terns Pharmaceuticals	Consultant	Self
Category: Consultant Description: Scientific Advisory Board Additional Information:		
Weight Watchers (WW) International	Consultant	Self

Entity	Type	Interest Held By
<i>Category:</i> Consultant <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		
Zealand Pharma A/S	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific Advisory Board <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Ania M Jastreboff, MD, PhD Lee M Kaplan, MD, PhD Juan P Frias, MD Qiwei Wu, PhD Yu Du, PhD Sirel Gurbuz, MD Tamer Coskun, MD, PhD Axel Haupt MD, PhD Zvonko Milicevic MD Mark L. Hartman, MD on behalf of the retatrutide phase 2 obesity trial investigators

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1122990

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Altimune	Consultant	Self
Category: Consultant Description: Additional Information:		
Amgen Inc.	Consultant	Self
Category: Consultant Description: Additional Information:		
Boehringer Ingelheim	Consultant	Self
Category: Consultant Description: Additional Information:		
Eli Lilly and Company	Consultant	Self
Category: Consultant Description: Additional Information:		
Gilead Sciences Inc	Consultant	Self
Category: Consultant Description: Additional Information:		
Novo Nordisk	Consultant	Self
Category: Consultant Description: Additional Information:		
Pfizer	Consultant	Self
Category: Consultant Description: Additional Information:		
Sidekick Health	Consultant	Self
Category: Consultant Description: Additional Information:		

Entity	Type	Interest Held By
twenty30.health	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Xeno Biosciences	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 782619

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Employment	Self
<i>Title:</i> Vice President <i>Additional Information:</i> Employee		<i>Position Description:</i> Clinical Research Physician

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

- a. **Please describe those relationships.**

Eli Lilly and Co. Stock holder

2. **What is the manuscript title?**

Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1122988

Disclosure Purpose: 23-01972

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Employment	Self
<i>Title:</i> Research advisor <i>Additional Information:</i>		<i>Position Description:</i> A research statistician that supports clinical trial development of diabetes drugs at Eli Lilly.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Triple Hormone Receptor Agonist Retatrutide: A Phase 2 Obesity Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.